iCAD Reports First Quarter 2016 Financial Results
Reports Progress with Reimbursement Under New CPT 3 Code for the Treatment of Nonmelanoma
Skin Cancer with Electronic Brachytherapy
Breast Tomosynthesis Cancer Detection U.S. Clinical Reader Study Meets Primary Endpoint;
Company Submits Final PMA Module to FDA
NASHUA, N.H. (May 3, 2016) – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced
image analysis, workflow solutions and radiation therapy for the early identification and treatment of
cancer, today reported financial results for the three months ended March 31, 2016.